Abstract: The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.

Abstract: A connector module comprises an insulating body, and further comprises a plurality of signal contact elements and a plurality of shield contact elements forming a connector face configured for establishing electric contact with a counterpart of the connector module. For each of the signal contact elements, there exist two or at most three shield contact elements that are closer to this signal contact element than any signal contact element of the plurality of signal contact elements. The signal contact elements are arranged along a first curve extending in the connector face of the connector module and the shield contact elements are arranged along a second curve extending in the connector face of the connector module, the first curve and the second curve being parallel curves having a predefined normal distance. Viewed along the course of the parallel curves, the signal contact elements and the shield contact elements are arranged alternatingly.

Abstract: A connector module comprises an insulating body, and further comprises a plurality of signal contact elements and a plurality of shield contact elements forming a connector face configured for establishing electric contact with a counterpart of the connector module. For each of the signal contact elements, there exist two or at most three shield contact elements that are closer to this signal contact element than any signal contact element of the plurality of signal contact elements. The signal contact elements are arranged along a first curve extending in the connector face of the connector module and the shield contact elements are arranged along a second curve extending in the connector face of the connector module, the first curve and the second curve being parallel curves having a predefined normal distance. Viewed along the course of the parallel curves, the signal contact elements and the shield contact elements are arranged alternatingly.

Abstract: A component for an electrical connector, said component bearing a field of electrically conducting signal elements (12) electrically insulated from each other and a field of electrically conducting shield elements (10), the shield elements being electrically interconnected with each other. For each of the signal elements (12), in any partial circumference extending over an angle (?) of more than 160 degrees from this signal element at least one of the shield element (10) is arranged that is closer to this signal element (12) than the any other signal element (12) of the field of signal elements (12). Each of these shield elements extends across an angle (?) of less than 160 degrees from the signal element (12). The number of shield elements (10) is the number of the signal elements (12) times 3 or less.

Abstract: A component for an electrical connector, said component bearing a field of electrically conducting signal elements (12) electrically insulated from each other and a field of electrically conducting shield elements (10), the shield elements being electrically interconnected with each other. For each of the signal elements (12), in any partial circumference extending over an angle (?) of more than 160 degrees from this signal element at least one of the shield element (10) is arranged that is closer to this signal element (12) than the any other signal element (12) of the field of signal elements (12). Each of these shield elements extends across an angle (?) of less than 160 degrees from the signal element (12). The number of shield elements (10) is the number of the signal elements (12) times 3 or less.

Abstract: The present invention relates to a method of producing a pharmaceutical preparation that contains a proton pump inhibitor and optionally a non-steroidal anti-inflammatory drug in the form of pellets. The invention further relates to pharmaceutical preparations obtainable by said method, in particular those with a defined dissolution profile.

Abstract: Described is a method for analyzing the metabolites of a biological sample which comprises quantitatively determining one or more metabolites in said sample in a way that said quantitative determination resolves isotopic mass differences within one metabolite, said method being characterized in that the sample comprises or is derived from a cell which has been maintained under conditions allowing the uptake of an isotopically labeled metabolizable compound so that the metabolites in said cell are saturated with the isotope with which said metabolizable compound is labeled. This method may further comprise, prior to quantitative determining the metabolites, combining the biological sample (i.e. the first biological sample) with a second biological sample in which the metabolites are not isotopically labeled or are isotopically labeled differently from the first biological sample; and determining in said biological samples the relative quantity of metabolites which differ by their isotopical label.

Abstract: Described is a method for analysing the metabolites of a biological sample which comprises quantitatively determining one or more metabolites in said sample in a way that said quantitative determination resolves isotopic mass differences within one metabolite, said method being characterized in that the sample comprises or is derived from a cell which has been maintained under conditions allowing the uptake of an isotopically labeled metabolizable compound so that the metabolites in said cell are saturated with the isotope with which said metabolizable compound is labeled. This method may further comprise, prior to quantitative determining the metabolites, combining the biological sample (i.e. the first biological sample) with a second biological sample in which the metabolites are not isotopically labeled or are isotopically labeled differently from the first biological sample; and determining in said biological samples the relative quantity of metabolites which differ by their isotopical label.